{
    "ticker": "CELU",
    "name": "Celularity Inc.",
    "description": "Celularity Inc. is a biotechnology company focused on the development of innovative cell therapy products to treat various diseases, including cancer and degenerative conditions. Founded in 2017 and headquartered in Warren, New Jersey, Celularity leverages its proprietary platform of placental-derived cells to create therapeutic solutions that harness the body's immune system. The company\u2019s mission is to improve the lives of patients through transformational therapies derived from human placental cells, which are rich in stem cells and have the potential to treat a wide range of health issues. Celularity is at the forefront of regenerative medicine and aims to advance the science of cell therapy, with a strong emphasis on clinical research and development. Its lead product candidates include a range of allogeneic cell therapies designed to treat hematologic malignancies and solid tumors, as well as products aimed at enhancing immune response in patients with various ailments. With a robust pipeline and a commitment to scientific excellence, Celularity is dedicated to delivering breakthrough therapies that make a meaningful difference in patient care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Warren, New Jersey, USA",
    "founded": "2017",
    "website": "https://www.celularity.com",
    "ceo": "Robert Hariri",
    "social_media": {
        "twitter": "https://twitter.com/Celularity",
        "linkedin": "https://www.linkedin.com/company/celularity/"
    },
    "investor_relations": "https://investors.celularity.com",
    "key_executives": [
        {
            "name": "Robert Hariri",
            "position": "CEO"
        },
        {
            "name": "Michele Garvey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy Products",
            "products": [
                "CYNK-001",
                "CYNK-101"
            ]
        },
        {
            "category": "Regenerative Medicine",
            "products": [
                "Placental-derived Stem Cells"
            ]
        }
    ],
    "seo": {
        "meta_title": "Celularity Inc. | Innovative Cell Therapy Solutions",
        "meta_description": "Explore Celularity Inc., a biotechnology company focused on developing innovative cell therapies derived from placental cells to treat cancer and other diseases.",
        "keywords": [
            "Celularity",
            "Cell Therapy",
            "Biotechnology",
            "Regenerative Medicine",
            "Cancer Treatment",
            "Stem Cells"
        ]
    },
    "faq": [
        {
            "question": "What does Celularity focus on?",
            "answer": "Celularity focuses on developing innovative cell therapy products derived from placental cells for various diseases."
        },
        {
            "question": "Who is the CEO of Celularity?",
            "answer": "Robert Hariri is the CEO of Celularity Inc."
        },
        {
            "question": "Where is Celularity headquartered?",
            "answer": "Celularity is headquartered in Warren, New Jersey, USA."
        },
        {
            "question": "What are Celularity's main products?",
            "answer": "Celularity's main products include CYNK-001 and CYNK-101, among other cell therapy solutions."
        },
        {
            "question": "When was Celularity founded?",
            "answer": "Celularity was founded in 2017."
        }
    ],
    "competitors": [
        "KITE",
        "CRSP",
        "ADMA"
    ],
    "related_stocks": [
        "VRTX",
        "GILD",
        "BMY",
        "AMGN"
    ]
}